Benzodiazepine dependence and withdrawal: A review of the syndrome and its clinical management

Acta Psychiatrica Scandinavica

Volumn 98, Issue SUPPL.S393, 1998, Pages 95-101

  Schweizer, E ^a   Rickels, K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Benzodiazepines; Dependence; Generalized anxiety disorder; Withdrawal syndrome

Indexed keywords

ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; 4 AMINOBUTYRIC ACID RECEPTOR; ABECARNIL; ALPIDEM; BENZODIAZEPINE RECEPTOR; BUSPIRONE; CARBAMAZEPINE; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CLONIDINE; FLUMAZENIL; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VALPROIC ACID; ZATOSETRON;

ADDICTION; ANIMAL; ANXIETY DISORDER; HUMAN; PSYCHOLOGICAL ASPECT; REVIEW; SYNDROME; TREATMENT OUTCOME; WITHDRAWAL SYNDROME; ANXIETY NEUROSIS; ARTICLE; BEHAVIOR THERAPY; BETA ADRENERGIC RECEPTOR BLOCKING; CLINICAL FEATURE; COGNITIVE THERAPY; DISEASE SEVERITY; DRUG CHOICE; DRUG DEPENDENCE; DRUG EFFICACY; PATHOPHYSIOLOGY; PREDICTION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; HUMANS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; SYNDROME; TREATMENT OUTCOME;

EID: 0031722787     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.1998.tb05973.x     Document Type: Article

References (39)

1. WEINTRAUB M, SINGH S, BYRNE L, MAHARAJ K, GUTTMACHER L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA, 1991: 266: 2392-2397.
2. SCHWEIZER E, RICKELS K. Buspirone and related 5-HT mn compounds as anxiolytics. In: NUTT DJ, MENDELSON WB, ed. Hypnotics and anxiolytics. London: Balliere Tindall, 1995:447-66.
3. LUDDENS H. KORPI ER. Biological function of GABA/benzodiazepine receptor heterogeneity. J Psychiatr Res 1995: 29: 77-94.
4. NEUSY AJ, LOWENSTEIN J. Blood pressure and blood press-ure variability following withdrawal of propranolol and clonidme. J Clin Pharmacol 1989: 29: 18-24.
5. KALES A, SCHARF MB, KALES JD. Rebound insomnia: a new clinical syndrome. Science 1978: 201: 1039-1041.
6. RICKELS K, FOX IL, GREENBLATT DJ, SANDLER KR, SCHLESS A. Clorazepatc and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry 1988: 145: 312-317.
7. TYRER P. Current problems with the benzodiazepines. In: WHEATLY D, ed. The anxiolytic jungle: where next? Chich-ester: J. Wiley & Sons Ltd., 1990: 23-60.
8. SCHARF MB, JACOBY JA. Lorazepam-efficacy, side-effects and rebound phenomena. Clin Pharmacol Ther 1982: 31: 175-179.
9. FONTAINE R, CHOUINARD G, ANNABLE L. Rebound anxiety in anxious patients after abrupt withdrawal of benzodiaze-pine treatment. Am J Psychiatry 1984: 141: 848-852.
10. HOLLISTER LE, MOTZENBECKER FP, DEGAN RO. Withdrawal reactions from chlordiazepoxide ('Librium'). Psychophar-macologia 1961: 2: 62-68.
11. Covi L, LIPMAN RS, PATTISON JH et al. Length of treatment with anxiolytic sedatives and response to their sudden with-drawal. Acta Psychiatr Scand 1973: 49: 51-64.
12. RICKELS K, SCHWEIZER E, CASE W G, GREENBLATT D. Long-term therapeutic use of benzodiazepines: effects of abrupt discontinuation. Arch Gen Psychiatry 1990: 47: 902.
13. ASHTON H. Benzodiazepine withdrawal: outcome in 50 pa-tients. Br J Addiction 1987: 82: 665-691.
14. SCHWEIZER E, RICKELS K, CASE WG, GREENBLATT DJ. Long-term therapeutic use of benzodizepines: effects of gradual taper. Arch Gen Psychiatry 1990: 47: 908-915.
15. HUMPHREYS SA, HALLSTROM C Benzodiazepine discon-tinuation phenomena. In: Balliere's clinical psychiatry. London: Balliere Tindall. 1995: 93-102.
16. SINGH L, LEWIS AS, FIELD MJ, HUGHES J, WOODRUFF GN. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci USA 1991: 88: 1130-1133.
17. CHOPIN P, BRILEY M. The benzodiazepine antagonist flu-mazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze. Psychopharma-cology 1993: 110: 409-414.
18. OLSEN RW, SAPP DW. Neuroactive steroid modulation of GABA receptors. Adv Biochem Psychopharmacology 1995: 48: 57-74.
19. MAJEWSKA MD. Neurosteroids: endogenous bimodal modulators of the GABA receptor: mechanism of action and physiological significance. Prog Neurobiol 1992: 38: 379-395.
20. SAVIC 1, WIDEN L, STONE-ELANDER S. Feasibility of revers-ing benzodiazepine tolerance with flumazenil. Lancet 1991: 337: 133-137.
21. TYRER P, RUTHERFORD D, HUGGETT T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1981: 1: 520-522.
22. CANTOPHER T, OLIVIERI S, CLEAVE N, EDWARDS JG. Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. Br J Psychiatry 1990: 156: 406-411.
23. GOODMAN WK, CHARNEY DS, PRICE LH, WOODS SW, HEN-INGER GR. Ineffectiveness of clonidine in the treatment of the benzodiazepine withdrawal syndrome: report of three cases. Am J Psychiatry 1986: 143: 900-903.
24. LADER M, FARR I, MORTON S. A comparison of alpidem and placebo in relieving benzodiazepine withdrawal symptoms. Int Clin Psychopharmacology 1993: 8: 31-36.
25. MAJEWSKA MD, HARRISON NL, SCHWARTZ RD, BARKER JL, PAUL SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986: 232: 1004-1007.
26. GEE KW, BRINTON RE, CHANG WC, MCEWEN BS. Gamma aminobutyric acid-dependent modulation of the chloride ionophore by steroids in rat brain. Eur J Pharmacology 1987: 136:419.
27. SCHWEIZER E, CASE WG, GARCIA F, GREENBLATT DJ, RICK-ELS K. Progesterone co-administration in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and taper outcome. Psychopharmacology 1995: 117:424-429.
28. GENT JR BENTLEY M, FEELY M, HAIGH JRM. Benzodiaze-pine cross-tolerance in mice extends to sodium valproate. Eur J Pharmacology 1986: 128: 9 15.
29. ROY-BYRNE PP, WARD NG, DONNELLY PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry 1989: 50 (Suppl. 3): 44-48.
30. A PELT S, EMRICH HM. Sodium valproate in benzodiazepine withdrawal. Am J Psychiatry 1990: 147: 950-951.
31. KLEIN E, UHDE TW, POST RM. Preliminary evidence for the utility of carbamazepine in alprazolam withdrawal. Am J Psychiatry 1986: 143: 235-236.
32. RIES RK, ROY-BYRNE PR WARD NG, NEPPE V, CULLISON S. Carbamazepine treatment for benzodiazepine withdrawal. Am J Psychiatry 1989: 146: 536-537.
33. SCHWEIZER E, RICKELS K, CAGE WG, GREENBLAT D. Car-bamazepine treatment in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal severity and outcome. Arch Gen Psychiatry 1991:48: 448-152.
34. FILE SE, BALDWIN HA. Flumazenil: a possible treatment for benzodiazepine withdrawal anxiety. Lancet 1987: 2: 106-107.
35. GONSALVUS SF, GALLAGHR DW. Persistent reversal of toler-ance to anticonvulsant effects and GABAergic subsensitiv-ity by a single exposure to benzodiazepine antagonist during chronic benzodiazepine administration. J Pharmacol Exp Ther 1988: 244: 79-83.
36. SCHWEIZER E, RICKELS K. Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 1986: 143: 1590-1592.
37. LADER M, OLAJIDE D. A comparison of buspirone and pla-cebo in relieving benzodiazepine withdrawal symptoms. J Clin Psychopharmacology 1987: 7: 11-15.
38. DELLE CHIAIE R, PANCHERI P, CASACCHIA M, STRATTA P, KOTZALIDIS GD, ZIBELLINI M. Assessment of the efficacy of buspirone in patients affected by generalized anxiety dis-order, shifting to buspirone from prior treatment with lora-zepam: a placebo-controlled, double-blind study. J Clin Psychopharmacology 1995: 15: 12 19.
39. ANSSEAU M, DE ROECK J. Trazodone in benzodiazepine de-pendence. J Clin Psychiatry 1993: 54: 189-191.